Tag Archives: Boehringer Ingelheim

Boehringer Ingelheim: Global survey reveals the emotional and practical challenges facing people with idiopathic pulmonary fibrosis (IPF)

61% of IPF patients are worried or extremely worried about experiencing an acute IPF exacerbation1  Survey underlines the importance of appropriate support and coping mechanisms for patients living with IPF1 Healthcare teams emphasise the need of a strong support network … Read the full press release

Boehringer Ingelheim To Focus on Innovative Digital Solutions in Healthcare With Digital Lab “BI X”

New start-up as platform for digital transformation in data science, agile software development and user experience design Improvement of  human and animal health with innovative digital solutions BI X offers 50 new jobs at the company’s headquarters Investment of 10 … Read the full press release

Sanofi’s Merial and Boehringer Ingelheim’s CHC business swap successfully closed

Both companies will become global leaders in two different sectors of the pharmaceutical market Paris (France) and Ingelheim (Germany), 03-Jan-2017 — /EuropaWire/ — Sanofi and Boehringer Ingelheim confirmed today that the strategic transaction signed in June 2016, which consists of an … Read the full press release

Boehringer Ingelheim and China Southeast University Institute of Life Sciences to develop new treatment approaches for hearing loss

360 million people worldwide suffer from disabling hearing loss with no effective treatment available New collaboration with China Southeast University is part of the Research Beyond Borders (RBB) initiative, which aims to explore emerging science within and beyond Boehringer Ingelheim’s … Read the full press release

Boehringer Ingelheim: Risankizumab (formerly BI 655066) shown to be more effective than placebo in patients with moderately-to-severely active Crohn’s disease

After 12 weeks, approximately twice as many patients with moderate-to-severe Crohn’s disease, the majority of whom had previously failed treatment with one or more TNF antagonists,  achieved clinical remission with risankizumab compared with placebo1 Endoscopic remission was achieved in 15% … Read the full press release

Boehringer Ingelheim: EU grants marketing authorisation for Giotrif® for the treatment of patients with advanced squamous cell carcinoma (SqCC) of the lung

• Approval provides a new oral treatment option for patients with the second largest sub-type of non-small cell lung cancer (NSCLC), representing approximately 20-30% of NSCLC cases.1,2 • Approval of Giotrif® is based on results of the LUX-Lung 8 study, … Read the full press release

Boehringer Ingelheim announces results of LUX-Lung 7 trial for treatment of patients with advanced non-small cell lung cancer with EGFR mutations

• Results of global Phase IIb LUX-Lung 7 trial demonstrate afatinib superior in reducing the risk of lung cancer progression and the risk of treatment failure both by 27% compared to gefitinib1 • More patients on afatinib were free of … Read the full press release

Boehringer Ingelheim ranked among the 100 leading global innovators by Thomson Reuters

Ingelheim, 20-11-2015 — /EuropaWire/ — Boehringer Ingelheim has been named one of the most innovative companies worldwide in 2015. For the first time, the research-driven pharmaceutical company ranked among the 100 leading global innovators named by news agency Thomson Reuters. Thomson … Read the full press release

Boehringer Ingelheim launches campaign to raise public awareness of chronic obstructive pulmonary disease (COPD)

Your Time campaign calls for earlier action in COPD WHO expects COPD to be the third leading cause of death worldwide by 2030 – exceeded only by heart disease and stroke1 By the time most people know they have COPD, … Read the full press release

Boehringer Ingelheim: new data from two trials showing Spiolto® Respimat® provides significant quality of life improvements in patients with moderate to severe COPD

OTEMTO® 1&2 post-hoc analysis reinforces quality of life benefits provided by Spiolto® Respimat® right from the initial stage when patients first need maintenance therapy* Head-to-head ENERGITO® study shows superior lung function improvements with Spiolto® Respimat® versus LABA/ICS FDC AMSTERDAM, 29-9-2015 … Read the full press release

Accredited Symptomatic Asthma CME Launched on epgonline.org

Not for audiences in the US and Canada LONDON, 26-8-2015 — /EuropaWire/ — This week, epgonline.org, the website for healthcare professionals, welcomes the launch of a free symptomatic asthma Continuing Medical Education (CME) activity, available at epgonline.org/symptomatic-asthma/cme/. Accredited by the … Read the full press release

Boehringer Ingelheim, Eli Lilly announce positive top-line results from EMPA-REG OUTCOME

Ingelheim, Germany and Indianapolis, US, 24-8-2015 — /EuropaWire/ — Boehringer Ingelheim and Eli Lilly and Company today announced positive top-line results from EMPA-REG OUTCOME®. This is a long-term clinical trial investigating cardiovascular (CV) outcomes for Jardiance® (empagliflozin) in more than 7,000 … Read the full press release

Boehringer Ingelheim: Phase III clinical trial found that empagliflozin in combination with metformin reduces blood glucose levels in adults with type 2 diabetes

Initial combinations of empagliflozin and metformin in patients with T2D led to significant reductions in blood glucose vs. empagliflozin or metformin alone at 24 weeks Ingelheim, Germany and Indianapolis, US, 8-6-2015 — /EuropaWire/ — A Phase III clinical trial has … Read the full press release

Boehringer Ingelheim announced new data analyses from the pivotal Phase III TONADO® 1&2 studies (NCT01431274/NCT01431287)

In patients with no prior maintenance treatment, tiotropium/olodaterol Respimat® more than doubled the improvement in lung function* compared to Spiriva® Respimat® alone1 Tiotropium/olodaterol Respimat® showed efficacy across all COPD stages with greatest lung function improvements over Spiriva® Respimat® in early … Read the full press release

Hydra Biosciences and Boehringer Ingelheim enter research collaboration to identify small-molecule TRP inhibitors for the treatment of renal diseases and disorders

CAMBRIDGE, Massachusetts and INGELHEIM, Germany, 14-4-2015 — /EuropaWire/ — Hydra Biosciences, Inc., a leader in the field of transient receptor potential (TRP) channel modulation, and Boehringer Ingelheim today announced that they have entered into a worldwide research collaboration and license agreement to … Read the full press release

Boehringer Ingelheim released two GLORIA™-AF Registry Program analyses examining the use of anticoagulant treatments for stroke prevention in patients with atrial fibrillation

For Non-US/Non-UK/Non-Canadian Media New analyses highlight undertreatment of high-risk AF patients1,2 First Phase II data demonstrating anticoagulant prescribing patterns in North America now available from GLORIA™-AF Registry Program Results presented at American College of Cardiology 64th Annual Scientific Session & … Read the full press release

Boehringer Ingelheim: New Pradaxa® data for treatment of thromboembolic diseases to be presented at ESC Congress 2014, 30th August – 3rd September, 2014 in Barcelona

• HOTLINE: New results from RE-LY® compare the effect of warfarin and Pradaxa® on kidney function in patients requiring anticoagulation • HOTLINE: GLORIA™-AF Registry Program benchmarks patient characteristics and antithrombotic use for stroke prevention in AF worldwide For Non-US/Non-UK/Non-Canadian Media … Read the full press release

Boehringer Ingelheim announced new data analyses show positive treatment effect of Pradaxa® (dabigatran etexilate) in patients with acute deep vein thrombosis or pulmonary embolism

For media outside of the US, the UK & Canada only The efficacy and safety profile of Pradaxa® (dabigatran etexilate) was maintained regardless of patient characteristics1,2,3,4 Pooled safety data favour Pradaxa® treatment over warfarin and provide further reassurance1-4 The analysed … Read the full press release

Boehringer Ingelheim partners with Taizhou China Medical City to open leading veterinary manufacturing plant in Jiangsu Province, China

Ground-breaking ceremony for leading veterinary manufacturing plant in Taizhou/China Investment of 58 million Euro 200 job opportunities expected Taizhou, Jiangsu, China, and Ingelheim, Germany, 27-8-2013 — /EuropaWire/ — Today, the research driven pharmaceutical company Boehringer Ingelheim, in partnership with Taizhou China Medical … Read the full press release

950 treatment naïve genotype-1b patients enrolled for two of Boehringer Ingelheim pivotal Phase III interferon-free hepatitis C clinical trials

Over 950 patients have now been successfully enrolled in the pivotal Phase III HCVerso™1 and 2 trials The Phase III study programme includes treatment naïve patients, including those ineligible for interferon and patients with liver cirrhosis The milestone coincides with … Read the full press release

Boehringer Ingelheim to unveil new data on the novel oral anticoagulant (NOAC) Pradaxa® (dabigatran etexilate) during the ESC Congress 2013 in Amsterdam

For media outside of the US, the UK & Canada only Ingelheim, Germany, 26-8-2013 — /EuropaWire/ — Boehringer Ingelheim today announced the upcoming presentation of new data on the novel oral anticoagulant (NOAC) Pradaxa® (dabigatran etexilate) during the ESC Congress 2013 organised … Read the full press release

Boehringer Ingelheim and Eli Lilly presented clinical trials results evaluating linagliptin efficacy and safety in Asians with Type 2 Diabetes

2-7-2013 — /europawire.eu/ — New Phase III data presented at the American Diabetes Association 73rd Scientific Sessions® (ADA) showed linagliptin improved blood glucose control as monotherapy and in combination with metformin, in Asian people from China, Malaysia and the Philippines with … Read the full press release

Boehringer Ingelheim, Lilly released results of new meta-analysis regarding CV events in linagliptin Phase 3 trials presented at the American Diabetes Association

Ingelheim, Germany and Indianapolis, US, 1-7-2013 — /europawire.eu/ — Boehringer Ingelheim and Eli Lilly and Company today announced results from a new analysis of Phase III data demonstrating that treatment with the dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin is not associated with … Read the full press release